Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.650
-0.040 (-2.37%)
At close: Feb 11, 2026, 4:00 PM EST
1.680
+0.030 (1.82%)
After-hours: Feb 11, 2026, 7:36 PM EST

Allogene Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
3714475409072,1263,541
Market Cap Growth
-8.37%-17.32%-40.45%-57.34%-39.95%11.80%
Enterprise Value
2062481714571,6972,753
Last Close Price
1.662.133.216.2914.9225.24
PS Ratio
-20300.075685.985814.6318.64-
PB Ratio
1.171.061.061.362.323.28
P/TBV Ratio
1.181.061.061.362.323.28
EV/Sales Ratio
-11252.801803.612931.9914.87-
Debt / Equity Ratio
0.270.220.190.150.080.05
Net Debt / Equity Ratio
-0.53-0.48-0.69-0.62-0.42-0.72
Net Debt / EBITDA Ratio
0.790.831.181.302.263.09
Net Debt / FCF Ratio
1.051.001.481.841.864.28
Asset Turnover
-0000.10-
Quick Ratio
7.998.2912.159.699.628.85
Current Ratio
8.198.5412.389.849.788.96
Return on Equity (ROE)
-54.43%-55.13%-55.51%-43.00%-18.24%-37.03%
Return on Assets (ROA)
-27.34%-27.01%-26.84%-22.55%-9.94%-16.59%
Return on Capital Employed (ROCE)
-55.20%-50.20%-51.90%-43.70%-18.20%-22.80%
Earnings Yield
-56.83%-57.68%-60.59%-37.53%-8.56%-8.94%
FCF Yield
-42.62%-45.01%-44.29%-24.88%-9.70%-5.11%
Buyback Yield / Dilution
-17.65%-24.14%-9.63%-5.39%-12.84%-19.11%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q